Summit Therapeutics plc (AIM: SUMM, NASDAQ: SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and Clostridium difficile infection, will announce its financial results for the third quarter and nine months ended 31 October 2017 on 6 December 2017.

About Summit Therapeutics

Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease, Duchenne muscular dystrophy, and the infectious disease, Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit

 

 

Glyn Edwards / Richard Pye (UK office)

Tel:

44 (0)1235 443 951

Erik Ostrowski / Michelle Avery (US office)

 

+1 617 225 4455

 

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Tel:

+44 (0)20 7213 0880

Liam Murray / Tony Rawlinson

 

 

 

 

 

N+1 Singer (Joint Broker)

Tel:

+44 (0)20 7496 3000

Aubrey Powell / Jen Boorer

 

 

 

 

 

Pamure Gordon (Joint Broker)

Tel:

+44 (0)20 7886 2500

Freddy Crossley, Corporate Finance

 

 

Tom Salvesen, Corporate Broking

 

 

 

 

 

MacDougall Biomedical Communications (US)

Tel:

+1 781 235 3060

Karen Sharma

 

ksharma@macbiocom.com

 

 

 

Consilium Strategic Communications (UK)

Tel:

+44 (0)20 3709 5700

Mary-Jane Elliott / Jessica Hodgson /

 

summit@consilium-comms.com